Gino In

Associate Professor of Clinical Medicine

Image of Gino In
Is this your profile? Click to edit

Overview

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Awards

  • University of Southern California: Chief Medical Oncology Fellow

Education and Training

  • University of Southern California, Los Angeles, CA — Fellowship — 2016 — Hematology/Oncology
  • SUNY Downstate Medical Center, Brooklyn, NY — Residency — 2011 — Internal Medicine
  • SUNY Downstate Medical Center, Brooklyn, NY — Internship — 2010
  • Ross University, North Brunswick Township, NJ — MD — 2010 — Medicine
  • Emory University, Atlanta, GA — MPH — 2006 — Environmental/Occupational Health
  • Emory University, Atlanta, GA — BS — 2002

Research Keywords

  • Medical Oncology
  • Skin Cancer
  • Melanoma
  • Acral Lentiginous Melanoma
  • Uveal Melanoma
  • Mucosal Melanoma
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Dermatofibrosarcoma Protuberans
  • Porocarcinoma

Publications

  • Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma. Cancers (Basel). 2026 Sep 18; 18(18).. View in PubMed
  • Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). Front Oncol. 2026; 16:1798502.. View in PubMed
  • Development of Poliosis in Patients Treated With Immunotherapy for Metastatic Cutaneous and Non-Cutaneous Melanoma. Pigment Cell Melanoma Res. 2026 May; 39(3):e70089.. View in PubMed
  • Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and Taxane Chemotherapy. Clin Case Rep. 2026 Mar; 14(3):e72247.. View in PubMed
  • Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2026; 18:17588359261423890.. View in PubMed
  • Ancestry and somatic profile indicate acral melanoma origin and prognosis. Nature. 2026 03; 651(8104):221-230.. View in PubMed
  • Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Feb; 7(2):272-282.. View in PubMed
  • Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov; 31(11):3933.. View in PubMed
  • Multiple Primary Acral Lentiginous Melanomas With BRCA1 Mutation. JAAD Case Rep. 2025 Nov; 65:30-33.. View in PubMed
  • Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Nov; 31(11):3668-3674.. View in PubMed